Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy

Inclusion Criteria: * Older than 20 years old and younger than 80 years old * Pathologically confirmed pancreatic ductal adenocarcinoma (metastatic or locally advanced stage) * ECOG Performance status ≤2 * Scheduled fot concurrent chemoradiation * Adequate liver function (total bilirubin \< 1.5 X the upper limits of normal (ULN), AST and ALT \<3 X UNL, and alkaline phosphatases \< 3 X ULN or \< 5 x ULN in case of liver involvement) * Adequate BM function (WBC ≥ 3,500/µl, absolute neutrophil cell count ≥ 1,500 /µl, platelet count ≥ 100,000/µl) * Not remarkable coagulation profile (PT \< 1.5 international normalized ratio(INR), aPTT \<35 sec) * Subjects who given written informed consent after being given a full description of the study Exclusion Criteria: * Coexisting of other malignancies within 5 years, except squamous cell carcinoma and basal cell carcinoma of the skin * Evidence of distant metastasis, such as liver, peritoneum and brain * history of receiving the chemoradiation for pancreatic cancer in the other hospital * History of receiving the operation which affect the anatomy of upper gastrointestinal tract * Any trouble for examination of upper endoscopy * Evidence of GI ulcers (A1\~H2) on endoscopy before start of chemoradiotherapy. * Use of aspirin, anti-platelet agent, anticoagulation agent, NSAIDs, or glucocorticoid within 1 week or enable to stop the administration (including start during chemoradiation) * Use of PPI, Histamine-2 receptor antagonist, antacid, prostaglandin, sucralfate within 2 weeks or enable to stop the administration * Patients who are unwilling or unable to provide informed consent, such as those with psychiatric problem, drug abuse or alcoholism